+

WO2008006105A3 - Genetic markers in the tachykinin nk1 receptor (tacr1) gene that correlate with asthma disorders - Google Patents

Genetic markers in the tachykinin nk1 receptor (tacr1) gene that correlate with asthma disorders Download PDF

Info

Publication number
WO2008006105A3
WO2008006105A3 PCT/US2007/073066 US2007073066W WO2008006105A3 WO 2008006105 A3 WO2008006105 A3 WO 2008006105A3 US 2007073066 W US2007073066 W US 2007073066W WO 2008006105 A3 WO2008006105 A3 WO 2008006105A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
asthma
tacr1
tachykinin
correlate
Prior art date
Application number
PCT/US2007/073066
Other languages
French (fr)
Other versions
WO2008006105A9 (en
WO2008006105A2 (en
Inventor
Eva Halapi
Hakon Hakonarson
Original Assignee
Decode Genetics Ehf
Eva Halapi
Hakon Hakonarson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf, Eva Halapi, Hakon Hakonarson filed Critical Decode Genetics Ehf
Publication of WO2008006105A2 publication Critical patent/WO2008006105A2/en
Publication of WO2008006105A9 publication Critical patent/WO2008006105A9/en
Publication of WO2008006105A3 publication Critical patent/WO2008006105A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Polymorphisms in the gene TACR1 are shown by association analysis to be a susceptibility gene for asthma. Methods of diagnosis of susceptibility to asthma, of decreased susceptibility to asthma and protection against asthma, are described, as are methods of treatment for asthma.
PCT/US2007/073066 2006-07-07 2007-07-09 Genetic markers in the tachykinin nk1 receptor (tacr1) gene that correlate with asthma disorders WO2008006105A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81919806P 2006-07-07 2006-07-07
US60/819,198 2006-07-07

Publications (3)

Publication Number Publication Date
WO2008006105A2 WO2008006105A2 (en) 2008-01-10
WO2008006105A9 WO2008006105A9 (en) 2008-04-03
WO2008006105A3 true WO2008006105A3 (en) 2008-08-14

Family

ID=38670544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/073066 WO2008006105A2 (en) 2006-07-07 2007-07-09 Genetic markers in the tachykinin nk1 receptor (tacr1) gene that correlate with asthma disorders

Country Status (1)

Country Link
WO (1) WO2008006105A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016399A2 (en) * 2000-08-25 2002-02-28 Genaissance Pharmaceuticals, Inc. Haplotypes of the tacr1 gene
EP1262565A2 (en) * 2001-05-25 2002-12-04 Pfizer Products Inc. Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases
JP2003259875A (en) * 2002-03-08 2003-09-16 Japan Science & Technology Corp Single base polymorphism (4) in human gene
WO2005100986A1 (en) * 2004-04-15 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with tachykinin receptor 1(tacr1)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016399A2 (en) * 2000-08-25 2002-02-28 Genaissance Pharmaceuticals, Inc. Haplotypes of the tacr1 gene
EP1262565A2 (en) * 2001-05-25 2002-12-04 Pfizer Products Inc. Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases
JP2003259875A (en) * 2002-03-08 2003-09-16 Japan Science & Technology Corp Single base polymorphism (4) in human gene
WO2005100986A1 (en) * 2004-04-15 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with tachykinin receptor 1(tacr1)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ADCOCK I M ET AL: "Increased tachykinin receptor gene expression in asthmatic lung and its modulation by steroids.", JOURNAL OF MOLECULAR ENDOCRINOLOGY AUG 1993, vol. 11, no. 1, August 1993 (1993-08-01), pages 1 - 7, XP009092353, ISSN: 0952-5041 *
ALMEIDA T A ET AL: "Tachykinins and tachykinin receptors: structure and activity relationships.", CURRENT MEDICINAL CHEMISTRY AUG 2004, vol. 11, no. 15, August 2004 (2004-08-01), pages 2045 - 2081, XP002459773, ISSN: 0929-8673 *
DATABASE EMBL [online] ebi; 6 May 2004 (2004-05-06), "human SNP", XP002479802, retrieved from EMBL Database accession no. ADK91051 *
DATABASE SNP [online] nih; 17 February 2004 (2004-02-17), XP002459774, retrieved from NCBI.NLM.NIH.GOV Database accession no. ss16811250 *

Also Published As

Publication number Publication date
WO2008006105A9 (en) 2008-04-03
WO2008006105A2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
HK1117569A1 (en) Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus
EP2064345A4 (en) Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
EP2024018A4 (en) Portable assemblies, systems, and methods for providing functional or therapeutic neurostimulation
WO2007027509A3 (en) Evaluating and treating scleroderma
EP2318088A4 (en) Portable assemblies, systems, and methods for providing functional or therapeutic neurostimulation
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
WO2008061213A3 (en) Genetic variations associated with tumors
WO2011153553A3 (en) Methods and compositions for kinase inhibition
WO2009108860A3 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
EP1926491A4 (en) Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
WO2008028044A9 (en) Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel
WO2009086215A3 (en) Pathway analysis of cell culture phenotypes and uses thereof
GB2477868A (en) Methods and systems for incorporating multiple environmental and genetic risk factors
WO2009061381A3 (en) Alpha-amylase variants with altered properties
WO2007107789A3 (en) Treatment of cns conditions
WO2007025177A3 (en) Neurogenesis by muscarinic receptor modulation
IL198677A0 (en) Compositions and methods for diagnosing, treating , and preventing prostate conditions
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2011044458A8 (en) Compositions and methods for diagnosing genome related diseases and disorders
WO2005094370A3 (en) Oligonucleotide complex compositions and methods of use as gene alteration tools
WO2008136989A3 (en) Polymorphisms in genes affecting sod2-related disorders and uses thereof
MX2010001993A (en) Methods and compositions for diagnosing disease.
WO2007124312A3 (en) Isolated polynucleotide molecules corresponding to mutant and wild-type alleles of the maize d9 gene and methods of use
WO2008088860A3 (en) Polymorphisms in the egfr pathway as markers for cancer treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07799409

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07799409

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载